On the other hand, one could take advantage of the side-effects of TRPV1 agonists—namely hypothermia—to effectively manage pathologies inducing hyperthermia-like heat stroke, for which no approved drug currently exists. The gene discussed is TRPV1; the disease is Heat Stroke.